Ovarian hyperstimulation syndrome: A review for emergency clinicians
- PMID: 31097257
- DOI: 10.1016/j.ajem.2019.05.018
Ovarian hyperstimulation syndrome: A review for emergency clinicians
Abstract
Introduction: A great deal of literature has recently evaluated the prevention and management of ovarian hyperstimulation syndrome (OHSS) in the outpatient setting, but there remains a dearth of research evaluating OHSS in the emergency department (ED) and its management.
Objective: This narrative review evaluates the underlying pathophysiology and clinical manifestations of OHSS and discusses approaches to patient care in the ED based on current literature.
Discussion: OHSS is an iatrogenic complication caused by an excessive response to controlled ovarian stimulation during assisted reproductive cycles (ART). OHSS complicates up to 30% of ART cycles, and many of these patients seek initial care in the ED. Risk factors for the development of OHSS include age < 35, history of polycystic ovarian syndrome or previous OHSS, and pregnancy. Emergency physicians will be faced with several complications including ascites, abdominal compartment syndrome, renal dysfunction, acute respiratory distress syndrome, thromboembolic disease, and hemodynamic instability. Critical patients should be evaluated in the resuscitation bay, and consultation with the primary obstetrics/gynecology team is needed, which improves patient outcomes. This review provides several guiding principles for management of OHSS and associated complications.
Conclusions: OHSS occurs in up to 30% of IVF cycles and carries a high morbidity. Effective care of the OHSS patient begins with early diagnosis while evaluating for other diseases and complications. Understanding these complications and an approach to the management of OHSS is essential to optimizing patient care.
Keywords: Ascites; Assisted reproductive technology; Effusion; Obstetrics; Ovarian hyperstimulation syndrome.
Published by Elsevier Inc.
Similar articles
-
Ovarian hyperstimulation syndrome.Crit Care Med. 2005 Oct;33(10 Suppl):S301-6. doi: 10.1097/01.ccm.0000182795.31757.ce. Crit Care Med. 2005. PMID: 16215351 Review.
-
Emergency department utilization for ovarian hyperstimulation syndrome.Am J Emerg Med. 2022 Oct;60:134-139. doi: 10.1016/j.ajem.2022.08.014. Epub 2022 Aug 8. Am J Emerg Med. 2022. PMID: 35964549
-
Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.Hum Reprod. 2016 Jun;31(6):1253-64. doi: 10.1093/humrep/dew051. Epub 2016 Apr 8. Hum Reprod. 2016. PMID: 27060174 Clinical Trial.
-
Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome.Fertil Steril. 2010 Sep;94(4):1399-1404. doi: 10.1016/j.fertnstert.2009.05.092. Epub 2009 Jul 9. Fertil Steril. 2010. PMID: 19591989
-
Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials.Hum Reprod. 2016 Sep;31(9):1997-2004. doi: 10.1093/humrep/dew149. Epub 2016 Jun 23. Hum Reprod. 2016. PMID: 27343272 Review.
Cited by
-
Systemic capillary leak syndrome.Nat Rev Dis Primers. 2024 Nov 14;10(1):86. doi: 10.1038/s41572-024-00571-5. Nat Rev Dis Primers. 2024. PMID: 39543164 Review.
-
[The best evidence for the management of ovarian hyper-stimulation syndrome in patients undergoing assisted reproductive therapy].Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024 Oct 25;53(5):632-640. doi: 10.3724/zdxbyxb-2024-0349. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024. PMID: 39319473 Free PMC article. Chinese.
-
Ovarian hyperstimulation syndrome.CMAJ. 2024 Sep 9;196(29):E1012. doi: 10.1503/cmaj.240213. CMAJ. 2024. PMID: 39251242 Free PMC article. No abstract available.
-
Exploring the Potential of In vitro Maturation (IVM) of Oocytes: Indications, Applications, and Treatment Protocols.Avicenna J Med Biotechnol. 2024 Jul-Sep;16(3):156-164. doi: 10.18502/ajmb.v16i3.15741. Avicenna J Med Biotechnol. 2024. PMID: 39132634 Free PMC article. Review.
-
Can We Harvest More Mature Oocytes by Repeating Gonadotropin-Releasing Hormone Agonist Doses in Polycystic Ovarian Syndrome Patients at Risk of OHSS in Antagonist Cycles? A Randomised Clinical Trial.Int J Fertil Steril. 2024 Jul 13;18(Suppl 1):48-54. doi: 10.22074/ijfs.2023.2008905.1513. Int J Fertil Steril. 2024. PMID: 39033370 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
